Secondary Data Studies

You are a company developing health products (drugs, medical devices) or an institutional Sponsor


RCTs will guide you through conception, implementation and publication of studies performed either from alone or paired secondary data (i.e. French Claim Data base SNDS/ registry) by probabilistic or direct pairing. Those data may come from:


  The French Claim Data base (SNDS : DCIR, EGB, PMSI)
  Clinical trials
  Registry or observational studies databases
  Connected devices
  Prospective studies

A methodology and an access strategy best suited for:


  Any real-world evaluation: efficiency, good use, safety, therapeutic strategy, etc.
  Your Market Access Studies: Targeted or Reached Population, disease burden
  Your cost studies for the development of models for the CEESP
  Your post-registration studies at the request of authorities

Depending on your needs, RCTs allows you to benefit from its expertise:


  In the dynamic analysis of healthcare pathways with data-science and AI methods
  In pharmaco-economics
  In epidemiology and pharmacoepidemiology (indicators for drug exposure)
  Dans la lecture de l’information codée dans le SNDS et l’élaboration d’algorithmes de sélection de populations et d’identification d’évènements d’intérêt
  In reading coded information in the SNDS and in developing algorithms for selecting populations and identifying events of interest
In Big Data analysis, with over 30 years of experience in biometry and mastery of analytical tools that will optimize the use of secondary data (propensity score, modelling, clustering)

We have already accompanied them

Assessment of the impact of the delisting of a therapeutic class in France: the AASAL case

Our expert is available for you

Audrey Lajoinie
Head of Secondary Use Data Studies - Member of the Real World Data working group

Next expertise

Health economics Learn more

Do you need a strong
partner to rely on ?


Let’s talk about it